Pfizer Inc. today announced positive topline results from the final prespecified overall survival analysis of the TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in ...

(RTTNews) - Pfizer (PFE) said that the U.S. Food and Drug Administration has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide ...

Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of certain patients with prostate cancer. Read more here.

Pfizer’s prostate cancer therapy Talzenna, when combined with Xtandi, can extend overall survival (OS) by nearly nine months over the standard of care (SoC), according to a Phase III trial.

Meanwhile, Pfizer reports a significant survival benefit in prostate cancer patients from its TALAPRO-2 study, furthering the impact of Talzenna in combination with Xtandi. España.

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI ®, an androgen receptor ...

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer. Feb. 13, 2025 10:00 AM ET Pfizer Inc. (PFE), PFE:CA.

NEW YORK, October 10, 2024--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA ...

Pfizer Inc. announced positive results from the phase 3 TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases.